CAPITALSTARS PRESENTS EQUITY MARKET UPDATE : 6 FEB 2020

INDIAN FACE  

                      

INDIAN EQUITY BENCHMARK
The S&P BSE Sensex added 163 points or 0.4 per cent to settle at 41,306 levels while the NSE's Nifty50 closed the session at 12,138, up 49 points or 0.4 per cent. On the NSE, the Nifty50 index ended at 12,138, up 49 points or 0.4 per cent. Bank and financial services stocks made impressive gains post the RBI policy announcement. Nifty Bank climbed 285 points or nearly a per cent to end at 31,287 while Nifty PSU Bank index closed at 2,312 levels, up 59 points or 2.63 per cent. Nifty Private Bank index rallied around a per cent to settle at 17,243 levels.

GLOBAL FACE

Asian Market- Asian markets rise, but the coronavirus outbreak isn't over. The market recovery is underway in Asia, even as the coronavirus outbreak continues to escalate

U.S. Market- U.S. Stocks Rally to Record, Treasuries Slump. U.S. stocks rallied to an all-time high, while Treasuries slumped on speculation efforts will succeed at minimizing the economic impact from the coronavirus. Crude oil rallied after tumbling into a bear market. The S&P 500 Index’s three-day gain topped 3%, and the Nasdaq indexes added to records.

European markets- Japan's Nikkei 225 (N225) advanced 2.4% on Thursday, South Korea's KOSPI (KOSPI) rose 2.9%, Hong Kong's Hang Seng Index (HSI) rose 2.6% and China's Shanghai Composite Index (SHCOMP) advanced 1.7% — all of them building on Wednesday's gains.

NIFTY SPOT

MARKET TALKS

Sun Pharma's Q3 net profit declines 26.4% yoy
Sun Pharma today announced results for the quarter ended December 2019. For Q3FY20, the company's revenue came in at Rs8,155cr, up 5.4% yoy vs. Rs7,740cr registered in the same quarter previous year. The company's net profit at Rs913.5cr was lower by 26.4% in the quarter under review vs. Rs1, 241.9cr reported in Q3FY19. The EBITDA for the quarter stood at Rs1, 841.4cr vs. Rs2,153cr in Q3FY19, down 14.5% yoy. The company's margins for the quarter came in at 22.6%, down 520bps yoy vs. 27.8% in Q3FY19.

Lupin's net loss widens at Rs835cr in Q3; exceptional loss of Rs289cr
Pharma major Lupin Ltd posted a consolidated loss at Rs835cr in December quarter from Rs151.75cr in the same quarter last year. Exceptional losses for the quarter stood at Rs288.68cr, which were less than Rs342.22cr in the same quarter last year. The pharma company’s revenue fell by 5% yoy at Rs3, 769cr in Q3FY20 as against Rs3,947cr in the same quarter last year. However, its tax expenses for the quarter jumped to Rs767cr.

Eicher Motors surges more than 4% despite a fall in Q3 net profit and EBITDA
Eicher Motors today announced the results for the quarter ending December 2019. For Q3FY20, the company's revenue came in at Rs2,363.5cr, up 0.7% yoy vs. Rs2,346cr registered in the same quarter previous year. The company's net profit at Rs488.9cr was lower by 2.5% in the quarter under review vs. Rs501.4cr reported in Q3FY19.

Maruti Suzuki unveils powerful and stylish Vitara Brezza BS6 Petrol
Maruti Suzuki India Limited unveiled the allnew Vitara Brezza, equipped with the powerful 1.5 Litre K-series BS6 petrol engine. The latest version of the country’s best-selling compact SUV, the Vitara Brezza, offers enhanced sportiness, bolder looks, stronger stance, premium interiors and a host of new features. Offering a complete package of power, convenience, comfort and premium-ness, the all-new Vitara Brezza ensures an enhanced driving experience for customers. Launched in 2016, the Vitara Brezza became an instant hit as it took the market by storm, emerging as the most awarded compact SUV. Its dominance over the segment is evident from the fact that in less than 4 years of its launch the Vitara Brezza has sold over 500,000 units. Vitara Brezza is the fastest to achieve the milestone in the SUV segment.

NAME OF THE STOCK : PEL

DATE :  6/1/2020

SEGMENT : CASH

CHART TYPE : Candlestick

EXCHANGE : NSE

VOLUME.MACD, RSI. : TECHNICAL INDICATORS USED

INVESTMENT ADVICE: CS CALL - BUY PEL IN CASH NR CMP 1570 TGT 1610 SL 1540.

RATIONALE FOR ARRIVING INVESTMENT ADVICE: We Provide Trading calls on the basis of the following key points:

1. Technical Analysis (Use of Candlestick Charts, Technical Indicators like RSI, MACD, Stochastic, ADX etc,) 

2. Fundamentals of the Company 

3. Live Market News & Updates (Company related, Sector related, Economy related, political, Global news, etc.) 

4. Tracking of Market Data’s (GDP, IIP, CPI, WPI, TRADE BALANCE, etc.) 

5. Tracking of Market Events like (RBI POLICY, FED POLICY, ECB MEETING, and OPEC MEETING, etc.) 

6. Tracking of Market Trends like Bullish Trend, Bearish Trend, and Consolidation, etc.

DISCLAIMER

The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and upon sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as the only factor while making investment decisions. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets is always subjected to market risk.

CLICK HERE FOR GETTING DETAILS & JOIN OUR BEST ADVISORY  -

Visit our Link : https://www.capitalstars.com/free-trial

Visit My Website: https://www.capitalstars.com/

CAPITALSTARS CALL US : 9977499927

Derivatives Tips , Intraday Stock Tips , FreeTrading Tips, Sebi Registered advisory